Alcon showcases new phakic lens
Following CE mark approval last month, Alcon proudly showcased the latest offering to its lens family; the AcrySof phakic lens.
Following CE mark approval last month, Alcon proudly showcased the latest offering to its lens family; the AcrySof phakic lens.
Indicated for the treatment of moderate to high levels of myopia, this angle-supported phakic lens induced a gain of one or more lines of best corrected spectacle visual acuity (BSCVA) in over 50% of the 360 patients involved in a recent clinical trial. It also delivered significant improvements in uncorrected visual acuity (UCVA) that was on average better than 20/25. Furthermore, an impressive 95% of patients in the trial agreed that they would have the lens implanted again, given the choice.
Some patients were followed for up to three years and, during this time, only minimal central and peripheral endothelial cell loss was reported.
The AcrySof phakic lens is foldable, it is available in four lengths and in refractive power ranges from -6.0 to -16.5 D. The lens is not yet available in the US.
